Skip to content

ENDOBON® ROXLG50Recalls & reported problems

ZimVie US Corp LLC · ENDOBON® XENOGRAFT GRANULES LARGE PARTICLE 5.0ML · Class 2 · Implant

Data updated Oct 16, 2026 from official FDA records · Editorial policy

Adverse event reports
2
Deaths reported
0
Injuries reported
2
Recalls naming it
0

Summary

The FDA's MAUDE database contains 2 adverse event reports that list this exact device (DI 03599870097571), received between Jun 19, 2023 and Jun 19, 2023 — classified as 2 injuries.

The most frequently reported specific device problem is “Failure to Osseointegrate” (2 reports).

Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 16, 2026.

Most reported problems

Device problems

  • Failure to Osseointegrate2

Patient problems

  • Inadequate Osseointegration2
  • Inflammation2

Recent adverse event reports

The 2 most recent of 2 reports, in the reporter's own words as published by the FDA.

  • InjuryJun 19, 2023Failure to Osseointegrate; Failure to Osseointegrate

    NO FURTHER EVENT INFORMATION AVAILABLE AT THE TIME OF THIS REPORT.

    Patient problems: Inadequate Osseointegration; Inflammation

    MAUDE report 17150576 ↗
  • InjuryJun 19, 2023Failure to Osseointegrate; Failure to Osseointegrate

    NO FURTHER EVENT INFORMATION AVAILABLE AT THE TIME OF THIS REPORT.

    Patient problems: Inadequate Osseointegration; Inflammation

    MAUDE report 17150530 ↗

Other Bone grafting material, synthetic devices

All Bone grafting material, synthetic devices →

Sources and updates

How reports and recalls are matched · Editorial policy · Report an error on this page